Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Recruiting · NCT06966024 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
DCC-2812
What this trial is about
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
- Able to take oral medication
- If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
- Adequate organ function and electrolytes
- Key
Exclusion criteria
- Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
- Impaired cardiac function
- Major surgery within 28 days of the first dose of study drug
Where it is running
8 locations listed across 7 US states.
- Dana-Farber Cancer Institute - Boston, Massachusetts, United States
- University of Michigan - Ann Arbor, Michigan, United States
- Washington University School of Medicine - St Louis, Missouri, United States
- Cleveland Clinic - Cleveland, Ohio, United States
- Fox Chase Cancer Center - Philadelphia, Pennsylvania, United States
- Vanderbilt- Ingram Cancer Center - Nashville, Tennessee, United States
- NEXT Oncology, Austin - Austin, Texas, United States
- NEXT Oncology, San Antonio - San Antonio, Texas, United States